- Home
- GELS vs LPCN Comparison
GELS vs LPCN Comparison
Compare GELS & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GELS
- LPCN
- Stock Information
- Founded
- GELS 2018
- LPCN 1997
- Country
- GELS Australia
- LPCN United States
- Employees
- GELS N/A
- LPCN N/A
- Industry
- GELS
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- GELS
- LPCN Health Care
- Exchange
- GELS NYSE
- LPCN Nasdaq
- Market Cap
- GELS 15.8M
- LPCN 16.1M
- IPO Year
- GELS 2024
- LPCN N/A
- Fundamental
- Price
- GELS $1.51
- LPCN $3.42
- Analyst Decision
- GELS
- LPCN Strong Buy
- Analyst Count
- GELS 0
- LPCN 1
- Target Price
- GELS N/A
- LPCN $10.00
- AVG Volume (30 Days)
- GELS 4.7M
- LPCN 22.1K
- Earning Date
- GELS 02-15-2025
- LPCN 05-08-2025
- Dividend Yield
- GELS N/A
- LPCN N/A
- EPS Growth
- GELS N/A
- LPCN N/A
- EPS
- GELS N/A
- LPCN N/A
- Revenue
- GELS $95,618.00
- LPCN $3,674,834.00
- Revenue This Year
- GELS N/A
- LPCN N/A
- Revenue Next Year
- GELS N/A
- LPCN N/A
- P/E Ratio
- GELS N/A
- LPCN N/A
- Revenue Growth
- GELS N/A
- LPCN N/A
- 52 Week Low
- GELS $0.77
- LPCN $2.75
- 52 Week High
- GELS $5.50
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- GELS N/A
- LPCN 55.02
- Support Level
- GELS N/A
- LPCN $2.68
- Resistance Level
- GELS N/A
- LPCN $3.50
- Average True Range (ATR)
- GELS 0.00
- LPCN 0.32
- MACD
- GELS 0.00
- LPCN -0.00
- Stochastic Oscillator
- GELS 0.00
- LPCN 74.89
About GELS GELTEQ LIMITED
Gelteq Ltd is a clinical and science-based company that is focused on developing and commercializing white-label gel-based delivery solutions to preserve the simplicity, accessibility and efficacy of oral delivery without the impediments traditionally associated with other oral delivery methods, with prescription drugs, nutraceuticals, pet care, and other products. It is engaged in the development and testing of a gel-based delivery system for humans and pets. Its principal products are edible gels.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.